118 results on '"Darcy, K.M."'
Search Results
2. Excellent versus poor response to neoadjuvant chemotherapy is accompanied by unique proteomic alterations in post versus pretreatment HGSOC tumors
3. Characterization of isogenic ovarian cancer cell line models of acquired resistance to the clinical ATR inhibitor AZD6738
4. Use of a clinical score to predict chemotherapy response in stage I mucinous ovarian cancers
5. The survival advantage of adjuvant chemoradiotherapy in surgically managed patients with FIGO stages I-III uterine carcinosarcoma treated in Commission on Cancer®-accredited facilities
6. Proteomic evaluation of the fallopian tube: Insight into the pathogenesis of serous ovarian cancer
7. Impact of histology on disparities in survival between non-Hispanic black and non-Hispanic white women with epithelial ovarian cancer in Commission on Cancer®-accredited facilities
8. Age matters when predicting overall survival benefit of combined chemotherapy and radiation versus radiation alone in high risk endometrial cancer: A study of 20,000 women using PORTEC-3 criteria
9. Racial disparities in cancer-specific survival between 1973 and 2015 persist for uterine cancer and are growing for breast, ovarian and cervical cancer
10. Not immune from disparity: Two decades of racial minority participation in immunotherapy trials for breast and gynecologic cancers
11. Survival trends in gynecologic malignancies display modest progress and persistent challenges: An investigation of future opportunities
12. Factors to explain racial disparity in survival for women with uterine cancer: Further investigations by histologic subtype
13. Biomarker panel for early detection of endometrial cancer in the prostate, lung, colorectal, and ovarian cancer screening trial
14. Survival in elderly patients with vulvar cancer: A National Cancer Database study
15. Treatment and survival in elderly women with gynecologic cancer not inferior with Medicare versus private insurance: A National Cancer Database investigation
16. The contributory factors to racial disparity in survival varied in uterine versus ovarian carcinosarcoma: A National Cancer Database investigation
17. Tumors from ovarian cancer patients receiving neoadjuvant chemotherapy have unique protein profiles that associate with volume of residual disease after interval debulking surgery
18. Histology matters in developing a framework for explaining racial disparity in cervical cancer survival
19. Trends in uterine cancer incidence in the United States and Asian countries: A population analysis of 576,558 of women
20. Racial disparities in incidence and mortality in adenocarcinoma or adenosquamous carcinoma compared with squamous cell carcinoma of the cervix
21. Risk stratification in serous ovarian cancer using a classifier based on 30 transcripts
22. Impact of age at diagnosis on racial disparities in endometrial cancer patients
23. GOG 8035: Nuclear BRCA1 loss may identify a poor prognostic subgroup of women with locally advanced cervical cancer treated with cisplatin-based chemoradiation: An NRG Oncology study
24. Disparities in the survival trends in epithelial ovarian cancer patients in the United States
25. CTNNB1 predicts better progression-free survival in endometrioid endometrial cancer patients treated with chemotherapy
26. Surrogates of progression-free survival in endometrial cancer patients: An evaluation of necrosis and other measures of tissue composition
27. Mutations and transcript expression of maternal embryonic leucine zipper kinase in endometrial cancer patients
28. MS7 a transcript-based diagnostic classifier for metastatic disease and worse progression-free survival in endometrioid endometrial cancer patients
29. Interim analysis of a phase I/IIA trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients
30. Racial differences in molecular subtypes between black and white patients with endometrial cancer
31. Proteogenomic alterations in black endometrioid endometrial cancer patients correlate with poor disease outcome
32. Racial and ethnic outcome differences in the top five women’s cancers: A harmonized Surveillance, Epidemiology, and End Results study for diagnoses from 2000-2014
33. Nestin: A biomarker of aggressive uterine cancers
34. Clinical assessments of MELK immunohistochemical expression in uterine cancer patients: A Gynecologic Cancer Center of Excellence study
35. A cost-effectiveness analysis of the AURELIA trial: Bevacizumab and paclitaxel offer a promising clinical and economic combination for platinum-resistant ovarian cancer
36. FIGO staging criteria is a meaningful clinical threshold for evaluating molecular signatures in serous ovarian cancer patients
37. Progestins and vitamin D inhibit CYP24A1 in vivo in ovarian cancer cell xenografts
38. Progestins inhibit calcitriol-induced CYP24A1 in endometrial and ovarian cancer cells
39. Interim analysis of a phase I/IIA trial assessing E39 + GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients
40. Diminished survival of separated, divorced, or widowed uterine cancer patients: A potential focus for survivorship programs
41. Phase I trial results of a folate receptor alpha-directed cancer vaccine (E39) in ovarian and endometrial cancer patients to prevent recurrence
42. Pharmacologic inhibition of polo-like kinase 1 enhances paclitaxel-based cell killing in taxol-resistant ovarian cancer cells
43. Ovarian cancers with nuclear special AT-rich sequence-binding protein 1 and cytoplasmic AT-rich interactive domain-containing protein 1A are rare, drug-resistant, and deadly
44. Curated Ovarian Database-derived identification of genes predicting survival in primary serous epithelial ovarian cancer
45. Proteomics of endometrial carcinogenesis: Identification of candidates underlying disease pathogenesis
46. Correlation of survival-stratified proteomic and curated gene data reveal a three-protein biomarker panel that predicts long-term survival of patients with primary epithelial ovarian cancer
47. Identification of candidate circulating cisplatin resistance biomarkers from epithelial ovarian carcinoma cell secretomes
48. Pathogenesis of ARID1A-driven gynecologic cancer
49. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer.
50. Progestins and vitamin D inhibit CYP24A1 in vivo in ovarian cancer cell xenografts
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.